scholarly journals Clinical outcome of Lu-177 PSMA in metastatic castration-resistant prostate cancer: An initial experience from a tertiary care cancer hospital

2020 ◽  
Vol 28 (2) ◽  
pp. 156-163
Author(s):  
Manoj Gupta ◽  
Ganesan Karthikeyan ◽  
Partha S. Choudhury ◽  
Anurag Sharma ◽  
Sudhir Rawal
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Tertiary Care ◽  
Initial Experience ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Cancer Hospital

scholarly journals Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone

2017 ◽  
Vol 8 (17) ◽  
pp. 3448-3455 ◽  
Author(s):  
Liancheng Fan ◽  
Chenfei Chi ◽  
Sanwei Guo ◽  
Yanqing Wang ◽  
Wen Cai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

2015 ◽  
Vol 67 (4) ◽  
pp. 795-802 ◽  
Author(s):  
Roberta Ferraldeschi ◽  
Daniel Nava Rodrigues ◽  
Ruth Riisnaes ◽  
Susana Miranda ◽  
Ines Figueiredo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Protein Loss ◽  
Pten Protein ◽  
Castration Resistant

Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naïve castration-resistant prostate cancer: Exploratory results from PREMIERE—A SOGUG trial.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 5052-5052 ◽  
Author(s):  
Albert Font Pous ◽  
Sergio Vazquez-Estevez ◽  
Aranzazu Gonzalez del Alba ◽  
Begoña Mellado ◽  
Ovidio Fernandez Calvo ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Clinical Outcome ◽  
Cox Regression ◽  
Castration Resistant Prostate Cancer ◽  
Exact Test ◽  
Castration Resistant ◽  
Expression Studies ◽  
Psa Response ◽  
Gene Expression Studies

5052 Background: Circulating tumor cells (CTCs) enumeration using CellSearch correlates with clinical outcome in prostate cancer, but is limited for gene expression analysis. AdnaTest ProstateCancer is a commercially available CTC immune-enrichment and PCR-related detection method that allows gene expression studies (Antonarakis E, NEJM 2014). It has demonstrated incremental detection of CTCs in patients with no CTCs identified by CellSearch (Samoila A, ASCO 2013) but needs to be clinically qualified. There is a strong need for studies to assess the association with the clinical outcome in CRPC. Methods: Between February and November 2015, 98 asymptomatic or oligo-symptomatic chemotherapy-naïve mCRPC pts were recruited in 16 institutions. Although initially designed to study the predictive value of TMPRSS2-ETS, data emerging after the trial was initiated led the group to prioritize alternative predefined exploratory biomarkers, including plasma AR (Grande E, ASC0 2017 #) and CTC characterization (Grande E, ESMO 2016). Outcome measures included PSA-PFS (sPFS), radiographic PFS (rPFS) and OS. Cox regression was used for survival analyses and Fisher’s exact test for PSA response. Results: Ninety-eight patients had CTC blood samples available. CTCs were detected at baseline, 12 weeks and progression in 36% (35/98), 27% (26/95) and 78% (32/41), respectively. The CTC conversion rate (positive to negative after 12 w) was 43% (15/35). All CTC conversions had ≥50% decline in PSA (15/15) whereas only 35% (7/20) of pts with persistent CTCs. At first interim analysis, with a median follow-up of 10.6 months, detection of CTCs at baseline was associated with worse sPFS (median, 7.59 m versus NR, HR, 3.67; 95% CI 1.90-7.10; P < 0.001), rPFS (median, 12.9 m versus NR; HR, 7.61; 95% CI, 2.80-20.64; P < 0.001) and OS (medians NR, HR, 9.51; 95% CI, 1.11-81.52; P = 0.0398). CTC positive pts were less likely to have a ≥90% decline in PSA (OR, 2.88; 95% CI, 1.13-7.72; P = 0.02). Conclusions: CTC detection using AdnaTest is associated with an adverse outcome in chemotherapy-naïve asymptomatic or oligo-symptomatic mCRPC pts. Clinical trial information: NCT02288936.

Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer

2016 ◽  
Vol 20 (3) ◽  
pp. 255-263 ◽  
Author(s):  
Vincenza Conteduca ◽  
Simon J. Crabb ◽  
Emanuela Scarpi ◽  
Catherine Hanna ◽  
Francesca Maines ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Outcome ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer

2014 ◽  
Vol 38 (5) ◽  
pp. 339-345 ◽  
Author(s):  
P. Beardo-Villar ◽  
M.J. Ledo-Cepero ◽  
R. Gavira-Moreno ◽  
M. Soto-Delgado ◽  
J. Soto-Villalba ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Abiraterone Acetate ◽  
Initial Experience ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document